Psoriasis - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 699
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P9BBBADC2E2EN
Leaflet:

Download PDF Leaflet

Psoriasis - Pipeline Review, H2 2016
Psoriasis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Psoriasis - Pipeline Review, H2 2016’, provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Psoriasis
  • The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
  • The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Psoriasis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Psoriasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Psoriasis Overview
Therapeutics Development
Psoriasis - Therapeutics under Development by Companies
Psoriasis - Therapeutics under Investigation by Universities/Institutes
Psoriasis - Pipeline Products Glance
Psoriasis - Products under Development by Companies
Psoriasis - Products under Investigation by Universities/Institutes
Psoriasis - Companies Involved in Therapeutics Development
Psoriasis - Therapeutics Assessment
Drug Profiles
Psoriasis - Dormant Projects
Psoriasis - Discontinued Products
Psoriasis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Psoriasis, H2 2016
Number of Products under Development for Psoriasis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Development by Companies, H2 2016 (Contd.4)
Number of Products under Development by Companies, H2 2016 (Contd.5)
Number of Products under Development by Companies, H2 2016 (Contd.6)
Number of Products under Development by Companies, H2 2016 (Contd.7)
Number of Products under Development by Companies, H2 2016 (Contd.8)
Number of Products under Development by Companies, H2 2016 (Contd.9)
Number of Products under Development by Companies, H2 2016 (Contd.10)
Number of Products under Development by Companies, H2 2016 (Contd.11)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Development by Companies, H2 2016 (Contd.5)
Products under Development by Companies, H2 2016 (Contd.6)
Products under Development by Companies, H2 2016 (Contd.7)
Products under Development by Companies, H2 2016 (Contd.8)
Products under Development by Companies, H2 2016 (Contd.9)
Products under Development by Companies, H2 2016 (Contd.10)
Products under Development by Companies, H2 2016 (Contd.11)
Products under Development by Companies, H2 2016 (Contd.12)
Products under Development by Companies, H2 2016 (Contd.13)
Products under Development by Companies, H2 2016 (Contd.14)
Products under Development by Companies, H2 2016 (Contd.15)
Products under Development by Companies, H2 2016 (Contd.16)
Products under Investigation by Universities/Institutes, H2 2016
Psoriasis - Pipeline by AbbVie Inc, H2 2016
Psoriasis - Pipeline by Abeome Corporation, H2 2016
Psoriasis - Pipeline by AbGenomics International, Inc., H2 2016
Psoriasis - Pipeline by Addex Therapeutics Ltd, H2 2016
Psoriasis - Pipeline by Advinus Therapeutics Ltd, H2 2016
Psoriasis - Pipeline by Affibody AB, H2 2016
Psoriasis - Pipeline by Albireo AB, H2 2016
Psoriasis - Pipeline by Almirall, S.A., H2 2016
Psoriasis - Pipeline by Alteogen Inc., H2 2016
Psoriasis - Pipeline by Amgen Inc., H2 2016
Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by AnaptysBio, Inc., H2 2016
Psoriasis - Pipeline by ApoPharma Inc., H2 2016
Psoriasis - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by Argos Therapeutics, Inc., H2 2016
Psoriasis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016
Psoriasis - Pipeline by AstraZeneca Plc, H2 2016
Psoriasis - Pipeline by Athenex, Inc., H2 2016
Psoriasis - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016
Psoriasis - Pipeline by Avexxin AS, H2 2016
Psoriasis - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
Psoriasis - Pipeline by BioApex, s.r.o., H2 2016
Psoriasis - Pipeline by BIOCAD, H2 2016
Psoriasis - Pipeline by Biocon Limited, H2 2016
Psoriasis - Pipeline by BioLingus AG, H2 2016
Psoriasis - Pipeline by BioMAS Ltd., H2 2016
Psoriasis - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016
Psoriasis - Pipeline by Bionomics Limited, H2 2016
Psoriasis - Pipeline by Bionovis SA, H2 2016
Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Psoriasis - Pipeline by Brickell Biotech, Inc., H2 2016
Psoriasis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Psoriasis - Pipeline by C4X Discovery Holdings PLC, H2 2016
Psoriasis - Pipeline by CalciMedica, Inc., H2 2016
Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
Psoriasis - Pipeline by Celgene Corporation, H2 2016
Psoriasis - Pipeline by Cell Medica Limited, H2 2016
Psoriasis - Pipeline by Cellceutix Corporation, H2 2016
Psoriasis - Pipeline by ChemoCentryx, Inc., H2 2016
Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H2 2016
Psoriasis - Pipeline by ChironWells GmbH, H2 2016
Psoriasis - Pipeline by Clonz Biotech Private Limited, H2 2016
Psoriasis - Pipeline by Coherus BioSciences, Inc., H2 2016
Psoriasis - Pipeline by Compugen Ltd., H2 2016
Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2016
Psoriasis - Pipeline by Creabilis SA, H2 2016
Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2016
Psoriasis - Pipeline by Curapel Limited, H2 2016
Psoriasis - Pipeline by Cutanea Life Sciences, Inc., H2 2016
Psoriasis - Pipeline by Dermala Inc, H2 2016
Psoriasis - Pipeline by Domainex Limited, H2 2016
Psoriasis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016
Psoriasis - Pipeline by EA Pharma Co Ltd, H2 2016
Psoriasis - Pipeline by Eli Lilly and Company, H2 2016
Psoriasis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by Exicure, Inc., H2 2016
Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Psoriasis - Pipeline by Forward Pharma A/S, H2 2016
Psoriasis - Pipeline by Gem Pharmaceuticals, LLC, H2 2016
Psoriasis - Pipeline by Genentech, Inc., H2 2016
Psoriasis - Pipeline by Genor BioPharma Co., Ltd., H2 2016
Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2016
Psoriasis - Pipeline by GlycoMar Limited, H2 2016
Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
Psoriasis - Pipeline by HitGen LTD, H2 2016
Psoriasis - Pipeline by Huabo Biopharm Co., Ltd., H2 2016
Psoriasis - Pipeline by Hydra Biosciences, Inc., H2 2016
Psoriasis - Pipeline by iCo Therapeutics Inc., H2 2016
Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by Immune Pharmaceuticals Inc., H2 2016
Psoriasis - Pipeline by Immune Response BioPharma, Inc., H2 2016
Psoriasis - Pipeline by Immungenetics AG, H2 2016
Psoriasis - Pipeline by Innovent Biologics, Inc., H2 2016
Psoriasis - Pipeline by Jenrin Discovery, Inc., H2 2016
Psoriasis - Pipeline by Johnson & Johnson, H2 2016
Psoriasis - Pipeline by Kadmon Corporation, LLC, H2 2016
Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by KPI Therapeutics, Inc., H2 2016
Psoriasis - Pipeline by Lead Pharma Holding B.V., H2 2016
Psoriasis - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Psoriasis - Pipeline by LEO Pharma A/S, H2 2016
Psoriasis - Pipeline by Lipidor AB, H2 2016
Psoriasis - Pipeline by Lupin Limited, H2 2016
Psoriasis - Pipeline by Lycera Corp., H2 2016
Psoriasis - Pipeline by mAbxience S.A., H2 2016
Psoriasis - Pipeline by Maruho Co., Ltd., H2 2016
Psoriasis - Pipeline by Medestea Research & Production S.p.A., H2 2016
Psoriasis - Pipeline by MediGene AG, H2 2016
Psoriasis - Pipeline by Merck KGaA, H2 2016
Psoriasis - Pipeline by MetrioPharm AG, H2 2016
Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Psoriasis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by Mycenax Biotech Inc., H2 2016
Psoriasis - Pipeline by NeuClone Pty Ltd, H2 2016
Psoriasis - Pipeline by Nimbus Therapeutics, LLC, H2 2016
Psoriasis - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
Psoriasis - Pipeline by Novan, Inc., H2 2016
Psoriasis - Pipeline by Novartis AG, H2 2016
Psoriasis - Pipeline by Nuevolution AB, H2 2016
Psoriasis - Pipeline by Numedii, Inc., H2 2016
Psoriasis - Pipeline by Oncobiologics, Inc., H2 2016
Psoriasis - Pipeline by OSE Immunotherapeutics, H2 2016
Psoriasis - Pipeline by Panacea Biotec Limited, H2 2016
Psoriasis - Pipeline by Pfizer Inc., H2 2016
Psoriasis - Pipeline by Pharis Biotec GmbH, H2 2016
Psoriasis - Pipeline by Pharmedartis GmbH, H2 2016
Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H2 2016
Psoriasis - Pipeline by Pieris Pharmaceuticals Inc, H2 2016
Psoriasis - Pipeline by PinCell srl, H2 2016
Psoriasis - Pipeline by Promius Pharma, LLC, H2 2016
Psoriasis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Psoriasis - Pipeline by Prothena Corporation Plc, H2 2016
Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by RedHill Biopharma Ltd., H2 2016
Psoriasis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by Sandoz International GmbH, H2 2016
Psoriasis - Pipeline by Sareum Holdings Plc, H2 2016
Psoriasis - Pipeline by Selvita S.A., H2 2016
Psoriasis - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016
Psoriasis - Pipeline by Shulov Innovative Science Ltd., H2 2016
Psoriasis - Pipeline by Sigmoid Pharma Limited, H2 2016
Psoriasis - Pipeline by Soligenix, Inc., H2 2016
Psoriasis - Pipeline by Spherium Biomed S.L., H2 2016
Psoriasis - Pipeline by Stemline Therapeutics, Inc., H2 2016
Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
Psoriasis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
Psoriasis - Pipeline by SWITCH Biotech LLC, H2 2016
Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2016
Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Psoriasis - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016
Psoriasis - Pipeline by Telormedix SA, H2 2016
Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Psoriasis - Pipeline by TheraMAB LLC, H2 2016
Psoriasis - Pipeline by Therapeutic Proteins International, LLC, H2 2016
Psoriasis - Pipeline by Therapix Biosciences Ltd., H2 2016
Psoriasis - Pipeline by UCB S.A., H2 2016
Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
Psoriasis - Pipeline by Wellstat Therapeutics Corporation, H2 2016
Psoriasis - Pipeline by XBiotech Inc, H2 2016
Psoriasis - Pipeline by XenoPort, Inc., H2 2016
Psoriasis - Pipeline by Yuhan Corporation, H2 2016
Psoriasis - Pipeline by Ziarco Pharma Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Psoriasis - Dormant Projects, H2 2016
Psoriasis - Dormant Projects (Contd.1), H2 2016
Psoriasis - Dormant Projects (Contd.2), H2 2016
Psoriasis - Dormant Projects (Contd.3), H2 2016
Psoriasis - Dormant Projects (Contd.4), H2 2016
Psoriasis - Dormant Projects (Contd.5), H2 2016
Psoriasis - Dormant Projects (Contd.6), H2 2016
Psoriasis - Dormant Projects (Contd.7), H2 2016
Psoriasis - Dormant Projects (Contd.8), H2 2016
Psoriasis - Dormant Projects (Contd.9), H2 2016
Psoriasis - Dormant Projects (Contd.10), H2 2016
Psoriasis - Dormant Projects (Contd.11), H2 2016
Psoriasis - Dormant Projects (Contd.12), H2 2016
Psoriasis - Dormant Projects (Contd.13), H2 2016
Psoriasis - Dormant Projects (Contd.14), H2 2016
Psoriasis - Dormant Projects (Contd.15), H2 2016
Psoriasis - Dormant Projects (Contd.16), H2 2016
Psoriasis - Dormant Projects (Contd.17), H2 2016
Psoriasis - Dormant Projects (Contd.18), H2 2016
Psoriasis - Dormant Projects (Contd.19), H2 2016
Psoriasis - Dormant Projects (Contd.20), H2 2016
Psoriasis - Dormant Projects (Contd.21), H2 2016
Psoriasis - Dormant Projects (Contd.22), H2 2016
Psoriasis - Dormant Projects (Contd.23), H2 2016
Psoriasis - Dormant Projects (Contd.24), H2 2016
Psoriasis - Dormant Projects (Contd.25), H2 2016
Psoriasis - Dormant Projects (Contd.26), H2 2016
Psoriasis - Dormant Projects (Contd.27), H2 2016
Psoriasis - Discontinued Products, H2 2016
Psoriasis - Discontinued Products (Contd.1), H2 2016
Psoriasis - Discontinued Products (Contd.2), H2 2016
Psoriasis - Discontinued Products (Contd.3), H2 2016
Psoriasis - Discontinued Products (Contd.4), H2 2016
Psoriasis - Discontinued Products (Contd.5), H2 2016

LIST OF FIGURES

Number of Products under Development for Psoriasis, H2 2016
Number of Products under Development for Psoriasis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

AbbVie Inc
Abeome Corporation
AbGenomics International, Inc.
Addex Therapeutics Ltd
Advinus Therapeutics Ltd
Affibody AB
Albireo AB
Almirall, S.A.
Alteogen Inc.
Amgen Inc.
Anacor Pharmaceuticals, Inc.
AnaptysBio, Inc.
ApoPharma Inc.
Arena Pharmaceuticals, Inc.
Argos Therapeutics, Inc.
Arrien Pharmaceuticals, LLC
AstraZeneca Plc
Athenex, Inc.
Aurigene Discovery Technologies Limited
Aurinia Pharmaceuticals Inc
Avexxin AS
Betta Pharmaceuticals Co. Ltd.
BioApex, s.r.o.
BIOCAD
Biocon Limited
BioLingus AG
BioMAS Ltd.
Biomics Biotechnologies Co., Ltd.
Bionomics Limited
Bionovis SA
Boehringer Ingelheim GmbH
Brickell Biotech, Inc.
Bristol-Myers Squibb Company
C4X Discovery Holdings PLC
CalciMedica, Inc.
Can-Fite BioPharma Ltd.
Celgene Corporation
Cell Medica Limited
Cellceutix Corporation
ChemoCentryx, Inc.
Chipscreen Biosciences Ltd
ChironWells GmbH
Clonz Biotech Private Limited
Coherus BioSciences, Inc.
Compugen Ltd.
Convoy Therapeutics, Inc.
Creabilis SA
Crescendo Biologics Limited
Curapel Limited
Cutanea Life Sciences, Inc.
Dermala Inc
Domainex Limited
Dr. August Wolff GmbH & Co. KG Arzneimittle
EA Pharma Co Ltd
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Exicure, Inc.
Foamix Pharmaceuticals Ltd.
Forward Pharma A/S
Gem Pharmaceuticals, LLC
Genentech, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
GlycoMar Limited
Grupo Ferrer Internacional, S.A.
HitGen LTD
Huabo Biopharm Co., Ltd.
Hydra Biosciences, Inc.
iCo Therapeutics Inc.
Idera Pharmaceuticals, Inc.
Immune Pharmaceuticals Inc.
Immune Response BioPharma, Inc.
Immungenetics AG
Innovent Biologics, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
Kadmon Corporation, LLC
KaloBios Pharmaceuticals, Inc.
KPI Therapeutics, Inc.
Lead Pharma Holding B.V.
Lee's Pharmaceutical Holdings Limited
LEO Pharma A/S
Lipidor AB
Lupin Limited
Lycera Corp.
mAbxience S.A.
Maruho Co., Ltd.
Medestea Research & Production S.p.A.
MediGene AG
Merck KGaA
MetrioPharm AG
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
NeuClone Pty Ltd
Nimbus Therapeutics, LLC
NovaLead Pharma Pvt. Ltd.
Novan, Inc.
Novartis AG
Nuevolution AB
Numedii, Inc.
Oncobiologics, Inc.
OSE Immunotherapeutics
Panacea Biotec Limited
Pfizer Inc.
Pharis Biotec GmbH
Pharmedartis GmbH
Phenex Pharmaceuticals AG
Pieris Pharmaceuticals Inc
PinCell srl
Promius Pharma, LLC
Protalix BioTherapeutics, Inc.
Prothena Corporation Plc
Provectus Biopharmaceuticals, Inc.
RedHill Biopharma Ltd.
Rigel Pharmaceuticals, Inc.
Sandoz International GmbH
Sareum Holdings Plc
Selvita S.A.
Shanghai Celgen Bio-Pharmaceutical Co., Ltd.
Shulov Innovative Science Ltd.
Sigmoid Pharma Limited
Soligenix, Inc.
Spherium Biomed S.L.
Stemline Therapeutics, Inc.
sterna biologicals Gmbh & Co KG
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
SWITCH Biotech LLC
Syntrix Biosystems, Inc.
Takeda Pharmaceutical Company Limited
Tasly Pharmaceutical Group Co., Ltd.
Telormedix SA
Teva Pharmaceutical Industries Ltd.
TheraMAB LLC
Therapeutic Proteins International, LLC
Therapix Biosciences Ltd.
UCB S.A.
Valeant Pharmaceuticals International, Inc.
Vitae Pharmaceuticals, Inc.
Wellstat Therapeutics Corporation
XBiotech Inc
XenoPort, Inc.
Yuhan Corporation
Ziarco Pharma Ltd
Skip to top


Chronic Plaque Psoriasis - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 125 pages

Ask Your Question

Psoriasis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: